Clinical Observation of Exosomes in Patients After Q-switched Laser Surgery
Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Feb 20, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special liquid dressing containing exosomes can help patients recover after undergoing a specific type of laser treatment called Nd:YAG laser 532. The goal is to see if this dressing can improve healing and skin regeneration in patients with certain skin conditions, like seborrheic keratosis or freckles.
To participate in this study, you should be between 65 and 74 years old and be able to follow the treatment rules for at least 8 weeks. It's important that you don’t have a history of keloids (thick, raised scars), are not pregnant or breastfeeding, and have not used any cosmetics with growth factors in the past six months. If you qualify and choose to join, you'll apply the dressing to one side of your face after the laser treatment and follow up with the study team to track your recovery. This trial is currently recruiting participants of all genders, and it offers a chance to contribute to understanding new ways to enhance skin healing after laser procedures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • It meets the diagnostic criteria of seborrheic keratosis or freckle;
- • pepole are able to follow the treatment rules of the study and were followed up for 8 weeks;
- • informed consent
- Exclusion Criteria:
- • History of keloids ;
- • Pregnancy or lactation;
- • Any cosmetics containing growth factor-related ingredients used within 6 months prior to treatment
- • Patients with incomplete observation data and incomplete course of treatment were excluded
About Nanjing First Hospital, Nanjing Medical University
Nanjing First Hospital, affiliated with Nanjing Medical University, is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care and cutting-edge medical practices, the hospital serves as a key player in the development of new therapies and treatment protocols. Its collaborative environment fosters interdisciplinary research, enabling the integration of scientific inquiry with clinical application. Nanjing First Hospital is committed to improving health outcomes and contributing to the global medical community through rigorous trial design and execution, ensuring the highest standards of ethical practice and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Trial Officials
Jie Dai
Principal Investigator
The First Affiliated Hospital with Nanjing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported